The improving OS HR and consistency across western and Asian populations de-risk the upcoming PDUFA date and support the drug's commercial potential. Traders should monitor FDA communication and any medical conference presentations of the detailed data. The November 14, 2026 PDUFA is the next major catalyst.
Price Chart
Executive Summary
Summit Therapeutics reported updated overall survival (OS) data from the Phase III HARMONi trial of ivonescimab plus chemotherapy in EGFR-mutated NSCLC. The hazard ratio improved to 0.76 in the full population and western subgroup, showing consistency across populations. The data has been submitted to the FDA ahead of the November 14, 2026 PDUFA date, strengthening the BLA package.
Key Facts
- Updated OS analysis hazard ratio 0.76 for full ITT population and western subgroup (June 2026 data cutoff)
- Western patient median follow-up 23.2 months; Asian patient median follow-up 32.7 months
- Prior primary OS analysis (April 2025) showed HR 0.79 (95% CI: 0.62-1.01; p=0.057) with median OS 16.8 vs 14.0 months
- September 2025 analysis showed HR 0.78 (95% CI: 0.62-0.98; nominal p=0.0332)
- BLA accepted by FDA with PDUFA goal date of November 14, 2026
- Acceptable and manageable safety profile consistent with prior Phase III data
Financial Impact
Positive clinical data strengthens the BLA for ivonescimab, a potential first-in-class bispecific antibody targeting PD-1 and VEGF. If approved, the drug could address a significant unmet need in EGFR-mutated NSCLC, a market with limited post-TKI options. No financial figures were disclosed in the filing.
Risk Factors
- Regulatory risk: FDA may request additional data or deny the BLA
- Competition from other PD-1/VEGF bispecifics and standard-of-care therapies
- Manufacturing and commercialization execution risk if approved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000058 |
| Document: a2026_prx0722xharmonidat.htm | 0001599298-26-000058 |
| Document: 0001599298-26-000058-index-headers.html | 0001599298-26-000058 |
| Document: 0001599298-26-000058-index.html | 0001599298-26-000058 |
| Document: 0001599298-26-000058.txt | 0001599298-26-000058 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $17.40 $17.85 | ▲ +2.59% | ▲ +1.77% | $16.75 (−3.71%) |
Sep 14, 2026 18d ago | 8-K | $18.42 $16.90 | ▼ −8.25% | ▼ −8.36% | $16.75 (−9.04%) |
Sep 3, 2026 29d ago | 8-K | $17.13 $17.55 | ▲ +2.45% | ▲ +3.60% | $16.75 (−2.19%) |
Aug 26, 2026 5w ago | 8-K | $14.23 $14.60 | ▲ +2.60% | ▲ +2.72% | $16.75 (+17.74%) |
Aug 5, 2026 8w ago | 8-K | $13.53 $15.10 | ▲ +11.60% | ▲ +11.25% | $16.75 (+23.84%) |
Jul 22, 2026 10w ago | 8-K | $14.74 $12.80 | ▼ −13.16% | ▼ −10.76% | $16.75 (+13.67%) |
Jun 12, 2026 16w ago | Insider Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.08 $14.07 | ▲ +7.57% | ▲ +7.14% | $16.75 (+28.10%) |
Jun 9, 2026 16w ago | S-3ASR | $13.05 $13.88 | ▼ −6.36% | ▼ −2.93% | $16.75 (−28.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access